Precigen, Inc.

The remaining change (an increase in other expense) primarily relates to an increase of $2.9 million in interest expenses related to long term debt that originated in the third quarter of 2025.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

In addition, the Company has $ 93,880 of long-term debt as of June 30, 2026 (see Note 9).

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

This additional capital could be raised through a combination of non-dilutive financings including debt and/or royalty financings, collaborations, strategic alliances, government, or other third-party funding, monetization of core and non-core assets, marketing, distribution or licensing arrangements, and/or dilutive financings including equity and/or debt financings which may include an equity component.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Investments As of June 30, 2026 and December 31, 2025 short-term and long-term investments include United States government debt and agency securities, certificates of deposit and corporate bonds.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

, more equity-like or debt-like).

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

In November 2024, the FASB issued ASU 2024-04 to improve the relevance and consistency in the application of induced conversion guidance in Subtopic 470-20, Debt Debt with Conversion and Other Options.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

“We are focused on converting hub enrollment into treated patients, and we look forward to building on this progress in the second quarter and beyond as more sites become activated, the impact of the permanent J-code takes hold, and our targeted site support helps deliver a seamless journey to treatment.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

The annual initiative is dedicated to educating the public and medical community about RRP by amplifying the voices of patients, caregivers, advocates, and the healthcare community supporting them.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

All statements, other than statements of historical facts, included in this Quarterly Report, including statements regarding our strategy; future events, including their outcome or timing; future operations; future financial position; future revenue; projected costs; prospects; plans; objectives of management; and expected market growth, are forward-looking statements.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

As part of a continuing effort to strategically prioritize the application of resources to particular development efforts, in 2024, the Company initiated a shutdown of ActoBio's operations.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what the Company expects.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

SEC original ↗Precigen, Inc. — Earnings release (8-K exhibit)EX-99May 13, 2026

Forward-looking statements are subject to risks, uncertainties, and other important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, including the important factors disclosed in this Quarterly Report, particularly in Part II, Item 1A, "Risk Factors.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Risks and Uncertainties As noted above, the Company is subject to a number of risks similar to those of other companies launching their first commercial product as well as conducting high-risk, early-stage research and development of therapeutic product candidates.

SEC original ↗Precigen, Inc. — 10-Q Quarterly report10-QAug 4, 2026